Immunotoxins pp 483-491 | Cite as

Treatment of leukemia patients with T101 ricin A chain immunotoxins

  • G. Laurent
  • A. E. Frankel
  • A. A. Hertler
  • D. M. Schlossman
  • P. Casellas
  • F. K. Jansen
Part of the Cancer Treatment and Research book series (CTAR, volume 37)


Cancer chemotherapies, despite recent advances, are still limited because of their toxic effects and lack of efficacy on the nonproliferating fraction of malignant cells. The use of agents which could target specifically malignant cells might improve the selectivity of systemic chemotherapy. As an illustration of the promise of this concept, some monoclonal antibodies (MoAb) directed against a tumor-associated antigen have been used in vivo to treat cancer patients, including non-B, non-T acute lymphoblastic leukemias (CALL) [1], T-ALL [2], B and T cell lymphomas [3–7], chronic lymphocytic leukemias (CLL) [8–10], or solid tumors [11–13].


Chronic Lymphocytic Leukemia Saturation Index Peripheral White Blood Cell Count Antigenic Modulation Killing Efficacy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ritz, J., Pesando, J.M., Sallan, S.E., Clavell, L.A., Notis-McConarty, J., Rosenthal P., and Schlossman, S.F. (1981) Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. Blood, 58, 141–152.PubMedGoogle Scholar
  2. 2.
    Bernard, A., Gosse, C., Pico, J., Favre, E., Raynal, B., Hayat, M., Lemerle, J., Charbord, P., and Boumsell, L. (1982) administration intraveineuse de l’anticorps monoclonal A50 chez un malade ayant une leucémie aiguë lymphoblastique à cellules T. Nouv. Presse Med., 11, 3173–3178.PubMedGoogle Scholar
  3. 3.
    Nadler, L.M., Stashenko, P., Hardy, R., Kaplan, W.D., Button, L.N., Kufe, D.W., Antman, K.H., and Schlossman, S.F. (1980) Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res., 40, 3147–3154.PubMedGoogle Scholar
  4. 4.
    Miller, R.A., Maloney, D.G., Warnke, R., and Levy, R. (1982) Treatment of B cell lymphoma with monoclonal antiidiotype antibody. N. Engl. J. Med., 306, 517–522.PubMedCrossRefGoogle Scholar
  5. 5.
    Miller, R.A., and Levy, R. (1981) Response of cutaneous T cell lymphoma to therapy with hybridoma monoclonal antibody. Lancet, 2, 226–230.PubMedCrossRefGoogle Scholar
  6. 6.
    Linch, D.C., Beverly, P.C., Newland, A., and Turnbull, A. (1983) Treatment of a low grade T cell proliferation with monoclonal antibody. Clin. Exp. Immunol., 51, 133–140.PubMedGoogle Scholar
  7. 7.
    Miller, R.A., Oseroff, A.R., Stratte, P.T., and Levy, R. (1983) Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood, 62, 988–995.PubMedGoogle Scholar
  8. 8.
    Dillman, R.O., Shawler, D.L., Sobol, R.E., Collins, H.A., Beauregard, J.C., Wormsley, S.B., and Royston, I. (1982) Murine monoclonal antibody therapy in two patients with chronic lymphocytic leukemia. Blood, 59, 1036–1045.PubMedGoogle Scholar
  9. 9.
    Foon, K.A., Schroff, R.W., Bunn, P.A., Mayer, D., Abrams, P.G., Fer, M., Ochs, J., Bottino, G.C., Sherwin, S.A., Carlo, D.J., Herberman, R.B., and Oldham, R.K. (1984) Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. Blood, 64, 1085–1093.PubMedGoogle Scholar
  10. 10.
    Dillman, R.O., Shawler, D.L., Dillman, J.B., and Royston, I. (1984) Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. J. Clin. Oncol., 2, 881–891.PubMedGoogle Scholar
  11. 11.
    Shen, J.W., Atkinson, B., Koprowski, H., and Sears, H. (1984) Binding of murine immunoglobulin to human tissues after immunotherapy with anticolorectal carcinoma monoclonal antibody. Int. J. Cancer, 33, 465–468.PubMedCrossRefGoogle Scholar
  12. 12.
    Schroff, R.W., Woodhouse, C.S., Foon, K.A., Oldham, R.K., Farrell, M., Klein, R.A., and Morgan, A.C. (1985) Intratumor localization of monoclonal antibody in patients with melanoma treated with antibody to a 250,000-dalton melanoma-associated antigen. J. Natl. Cancer Inst., 74, 299–306.PubMedGoogle Scholar
  13. 13.
    Houghton, A.N., Mintzer, D., Gordon-Caro, C., Welt, S., Fliegel, B., Vadhan, S., Carswell, E., Melamed, M.R., Oettgen, H.F., and Old, L.J. (1985) Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: A phase I trial in patients with malignant melanoma. Proc. Natl. Acad. Sci. USA, 82, 1242–1246.PubMedCrossRefGoogle Scholar
  14. 14.
    Royston, I., Majda, J.A., Baird, S.M., Meserve, B.L., and Griffiths, J. (1980) Human T cell antigens defined by monoclonal antibodies. The 65,000 dalton antigen of T cells (T65) is also found on chronic lymphocytic leukemia cells bearing surface immunoglobulin. J. Immunol., 125, 725–731.PubMedGoogle Scholar
  15. 15.
    Burn, B.F., Warnke, R.A., Doggett, R.S., and Rouse, R.V. (1983) Expression of a T cell antigen (leu 1) by B cell lymphomas. Am. J. Pathol., 113, 165–171.Google Scholar
  16. 16.
    Al Saati, T., Laurent, G., Caveriviere, P., Rigal, F., and Delsol, G. (1984) Reactivity of leu 1 and T101 monoclonal antibodies with B cell lymphomas. Clin. Exp. Immunol., 58, 631–637.PubMedGoogle Scholar
  17. 17.
    Gros, O., Gros, P., Jansen, F.K., and Vidal, H. (1985) Biochemical aspects of immunotoxin preparation. J. Immunol. Methods, 81, 283–297.PubMedCrossRefGoogle Scholar
  18. 18.
    Laurent, G., Pris, J., Farcet, J.P., Carayon, P., Blythman, H., Casellas, P., Poncelet, P., and Jansen, F.K. (1986) Effects of therapy with T101 ricin A-chain immunotoxin in two leukemia patients. Blood, 67, 1680–1687.PubMedGoogle Scholar
  19. 19.
    Hertler, A.A., Schlossman, D.M., Borowitz, M.J., Laurent, G., Jansen, F.K., Schmidt, C., and Frankel, A.E. (1987) A phase I study of T101 ricin A-chain immunotoxin in refractory chronic lymphocytic leukemia, submitted for publication.Google Scholar
  20. 20.
    Spitler, L.E., personal communication.Google Scholar
  21. 21.
    Casellas, P., Canat, X., Fauser, A.A., Gros, O., Laurent, G., Poncelet, P., and Jansen, F.K. (1985) Optimal elimination of leukemia T-cells from human bone marrow with T101 ricin A-chain immunotoxin. Blood, 65, 289–297.PubMedGoogle Scholar
  22. 22.
    Shawler, D.L., Miceli, M.C., Wormsley, S.B., Royston, I., and Dillman, R.O. (1984) Induction of in vitro and in vivo antigenic modulation by the anti-human T-cell monoclonal antibody T101. Cancer Res., 44, 5921–5927.PubMedGoogle Scholar
  23. 23.
    Bourrie, B., Casellas, P., Blythman, H., and Jansen, F.K. (1986) Study of the plasma clearance of antibody ricin A chain immunotoxins: Evidence for specific recognition sites on the A-chain that mediate rapid clearance of the immunotoxin. Eur. J. Biochem., 155, 1–10.PubMedCrossRefGoogle Scholar
  24. 24.
    Laurent, G., Kuhlein, E., Casellas, P., Canat, X., Carayon, P., Poncelet, P., Correll, S., Rigal, F., and Jansen, F.K. (1986) Determination of sensitivity of fresh leukemia cells to immunotoxins. Cancer Res., 46, 2289–2294.PubMedGoogle Scholar
  25. 25.
    Akiyama, S., Seth, P., Pirker, R., Fitzgerald, D., Gottesman, M.M., and Pastan, I. (1985) Potentiation of cytotoxic activity of immunotoxins on cultured human cells. Cancer Res., 45, 1005–1007.PubMedGoogle Scholar
  26. 26.
    Casellas, P., Bourrie, B., Gros, P., and Jansen, F.K. (1984) Kinetics of cytotoxicity induced by immunotoxins. Enhancement by lysosomotropic amines and carboxyl ionophores. J. Biol. Chem., 259, 9359–9364.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1988

Authors and Affiliations

  • G. Laurent
  • A. E. Frankel
  • A. A. Hertler
  • D. M. Schlossman
  • P. Casellas
  • F. K. Jansen

There are no affiliations available

Personalised recommendations